Avalo Therapeutics Statistics
Total Valuation
AVTX has a market cap or net worth of $448.71 million. The enterprise value is $55.89 million.
| Market Cap | 448.71M |
| Enterprise Value | 55.89M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AVTX has 57.82 million shares outstanding. The number of shares has increased by 201.16% in one year.
| Current Share Class | 57.82M |
| Shares Outstanding | 57.82M |
| Shares Change (YoY) | +201.16% |
| Shares Change (QoQ) | +26.28% |
| Owned by Insiders (%) | 1.43% |
| Owned by Institutions (%) | 95.20% |
| Float | 39.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7,605.21 |
| Forward PS | n/a |
| PB Ratio | 0.96 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 947.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.63, with a Debt / Equity ratio of 0.00.
| Current Ratio | 16.63 |
| Quick Ratio | 16.31 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.57% and return on invested capital (ROIC) is -206.93%.
| Return on Equity (ROE) | -33.57% |
| Return on Assets (ROA) | -19.69% |
| Return on Invested Capital (ROIC) | -206.93% |
| Return on Capital Employed (ROCE) | -20.89% |
| Weighted Average Cost of Capital (WACC) | 8.35% |
| Revenue Per Employee | $1,788 |
| Profits Per Employee | -$2.69M |
| Employee Count | 33 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AVTX has paid $166,000 in taxes.
| Income Tax | 166,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.71% in the last 52 weeks. The beta is 0.75, so AVTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -49.71% |
| 50-Day Moving Average | 12.33 |
| 200-Day Moving Average | 15.63 |
| Relative Strength Index (RSI) | 38.26 |
| Average Volume (20 Days) | 3,339,927 |
Short Selling Information
The latest short interest is 8.91 million, so 15.41% of the outstanding shares have been sold short.
| Short Interest | 8.91M |
| Short Previous Month | 11.96M |
| Short % of Shares Out | 15.41% |
| Short % of Float | 22.29% |
| Short Ratio (days to cover) | 3.45 |
Income Statement
In the last 12 months, AVTX had revenue of $59,000 and -$88.65 million in losses. Loss per share was -$2.58.
| Revenue | 59,000 |
| Gross Profit | -38.24M |
| Operating Income | -95.56M |
| Pretax Income | -88.49M |
| Net Income | -88.65M |
| EBITDA | -95.49M |
| EBIT | -95.56M |
| Loss Per Share | -$2.58 |
Balance Sheet
The company has $392.97 million in cash and $153,000 in debt, with a net cash position of $392.81 million or $6.79 per share.
| Cash & Cash Equivalents | 392.97M |
| Total Debt | 153,000 |
| Net Cash | 392.81M |
| Net Cash Per Share | $6.79 |
| Equity (Book Value) | 436.55M |
| Book Value Per Share | 8.10 |
| Working Capital | 376.64M |
Cash Flow
| Operating Cash Flow | -63.47M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 68,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -63.47M |
| FCF Per Share | -$1.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | -161,962.71% |
| Pretax Margin | -149,977.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -201.16% |
| Shareholder Yield | -201.16% |
| Earnings Yield | -33.27% |
| FCF Yield | -14.14% |
Analyst Forecast
The average price target for AVTX is $34.80, which is 348.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.80 |
| Price Target Difference | 348.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on December 29, 2023. It was a reverse split with a ratio of 1:240.
| Last Split Date | Dec 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:240 |
Scores
AVTX has an Altman Z-Score of 6.22 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.22 |
| Piotroski F-Score | 2 |